With ubituximab, a high percentage of patients maintained no signs of disease activity.

Published Date: 01 Mar 2023

After receiving ublituximab treatment, the majority of patients with relapsing multiple sclerosis showed that they could achieve and maintain no evidence of disease activity.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Liver cancer survival rates reflect income disparities

2.

Glofitamab Regimen Improves Survival in DLBCL

3.

Early breast cancer detection may be possible with a wearable ultrasound scanner.

4.

Chemoradiation Plus Immunotherapy Fails to Improve Survival in Limited-Stage SCLC

5.

ASCO: Vepdegestrant ups survival in ER+, HER2− advanced breast cancer with ESR1 mutations


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot